Elicio Therapeutics announced immunogenicity testing data from Phase 2 AMPLIFY-7P trial.
Approximately 99% of evaluable patients generated robust mKRAS-specific T cell responses with ELI-002 7P.
T cell responses showed an average increase of 145.3x over baseline, consistent with Phase 1 trial results.
T Cell Response Rate
99% of patients in Phase 2 trial showed mKRAS-specific T cell responses with ELI-002 7P.
Average Fold Change
T cell responses increased by an average of 145.3x over baseline, enhancing confidence in trial results.
IDMC Recommendation
Independent Data Monitoring Committee recommended continuing Phase 2 trial to final analysis, indicating preliminary efficacy signals.
- The strong T cell responses observed in the Phase 2 trial indicate promising immunogenicity of ELI-002 7P.
- Correlation between T cell responses and clinical activity in prior Phase 1 trials enhances confidence in potential therapeutic benefits.
Elicio Therapeutics' ELI-002 shows significant potential for cancer immunotherapy, with positive data supporting ongoing Phase 2 trial.